诺诚健华新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药

Core Viewpoint - The company announced the completion of the first patient dosing in a global Phase II clinical trial for its novel TYK2 inhibitor Soficitinib (ICP-332) aimed at treating nodular prurigo [1] Group 1: Product Development - Soficitinib is a highly efficient and selective oral TYK2 inhibitor developed by the company [1] - The drug is being developed for various T-cell related autoimmune diseases, with a strong focus on dermatological indications [1] Group 2: Market Potential - The current development strategy includes a deep focus on a wide range of skin-related conditions, including atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1]